Clinical Trial Search

Primary: Change From Baseline to the End of the Maintenance Period in Pain Severity Assessed Using an 11-point Likert Pain Scale — -2.2; -2.8 scores on a scale — p=0.172

Primary: High Contrast/High Illumination (HC/HI) Binocular Visual Acuity (VA) at Near — 0.10; 0.12; 0.08; 0.09 logMAR

Primary: Treatment Success Defined as Symptom Relief 3 Months After Treatment Based on an Eckhardt Score ≤ 3 — 1.4; 8.8 Eckardt Score — p=<0.001

Primary: Overall Response Rate — .083 proportion of participants

Primary: Continuous Whole Brain Imaging With Standard Imaging Parameters for Each Functional Magnetic Resonance Imaging (fMRI) Scan

Primary: Smoking Quit Rate by Number of Calls Received — 1; 35 Participants — p=<.01

Primary: Cmax - Maximum Steady-state Plasma Concentration — 31652 ng/mL

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Circulating Biomarkers — 926.3; 913.1; 1122.2; 1108.2 ng/ml

Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 27.3; 15.7; 444.6; 197.0 Titer

Primary: BLOOD PRESSURE LIPIDS — 126.6; 129.9 mmHG

Primary: Percentage of Subjects With Adverse Drug Reactions (ADRs) — 6.4 percent subjects

Primary: Total Fluoroscopy Time — 28.3 minutes

Primary: Estimated Percentage of Participants in Blood Pressure Control at Baseline — 61; 59; 53; 64 % of particpants w/ controlled BP

Primary: Progression Free Survival (PFS) as Assessed by Central Independent Review — 3.4; 2.7 months — p=0.0019